Adolor(ADLR)Maybe the Answer to the Pain of Owning Biotechs! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Adolor(ADLR)Maybe the Answer to the Pain of Owning Biotechs!

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: idos	3/12/2007 5:07:14 PM
	Read Replies (1) of 21

Adolor partner plans added Phase III study on its bowel drug Mon Mar 12, 2007 4:50 PM ET March 12 (Reuters) - Adolor Corp. <ADLR.O> said on Monday that its partner Glaxo Group Ltd. has planned an additional Phase III study to evaluate the efficacy and safety of the experimental bowel treatment drug, Entereg. Pacific Growth Equities analyst Gregory Wade pointed out that plans for the Phase III study, which will be conducted in second quarter, suggest that the data will not show any additional unfavourable safety issues. The drug, which GlaxoSmithKline Plc <GSK.L> and Adolor are developing in partnership, was delayed as the U.S. Food and Drug Administration had asked for additional data. In November, the FDA said it wanted to see 12-month safety data from an ongoing clinical trial of Entereg (alvimopan) as a treatment of opiate-induced bowel problems, including analysis of serious cardiovascular events. Shares of Adolor, a biopharmaceutical company, were slightly down at $8.31 in after-market electronic trade, after closing up 26.1 percent or $1.78 at $8.60 on the Nasdaq. (Reporting by Neha Pathania in Bangalore

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next